Clinical Trial Update: Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis [Phase 4]

View source ↗

Summary

Phase 4 trial comparing Rebif (interferon beta-1a) with Copaxone (glatiramer acetate) in relapsing-remitting multiple sclerosis; results have been posted after …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• COPAXONE (GLATIRAMER ACETATE)
• Rebif (interferon beta-1a)

Snippet

Sponsor: EMD Serono | Conditions: Relapsing-remitting Multiple Sclerosis | Phase 4 | Status: COMPLETED | Results posted: 2018-06-27